Pharmacological Targeting of Angiogenesis in Head and Neck Cancer: Molecular Mechanisms and Emerging Therapeutic Strategies
Pharmaceuticals · 18.06.2026 · 19 (6) · 950
DOI: 10.3390/ph19060950 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Pharmaceuticals, online erschienen am 18.06.2026. Verfasst von Diana Szekely und 7 weiteren Autor:innen. Beteiligte Einrichtung: Doctoral School, "Victor Babes" University of Medicine and Pharmacy Timisoara, E. Murgu Square, No. 2, 300041 Timisoara, Romania. Die Arbeit nennt 142 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Victor Babeș University of Medicine and Pharmacy Timișoara.
Abstract (Originalsprache)
Head and neck squamous cell carcinoma (HNSCC) remains one of the most aggressive and heterogeneous malignancies worldwide, characterized by high rates of locoregional recurrence, metastatic dissemination, and therapeutic resistance. Angiogenesis plays a central role in tumor progression by supporting vascular remodeling, hypoxia adaptation, invasion, immune evasion, and metastatic spread. In HNSCC, angiogenic activation is regulated through complex interactions involving hypoxia-inducible factors, vascular endothelial growth factor (VEGF) signaling, stromal remodeling, inflammatory pathways, and epigenetic mechanisms within the tumor microenvironment. Recent evidence has also highlighted the role of non-coding RNAs, particularly microRNAs, and exosome-mediated communication in modulating angiogenic and immune-related signaling pathways. Although antiangiogenic therapies, including monoclonal antibodies and tyrosine kinase inhibitors, have demonstrated biological activity in HNSCC, their clinical efficacy remains limited by tumor heterogeneity, adaptive resistance mechanisms, toxicity, and the lack of validated predictive biomarkers. Several emerging therapeutic strategies are under preclinical or early clinical investigation in HNSCC, including miRNA-based approaches, nanoparticle-assisted delivery systems, vascular normalization concepts, and combinations with immune checkpoint inhibitors; however, robust clinical evidence for most of these strategies remains limited, and their translation to routine practice requires further validation. This review provides a comprehensive overview of the molecular mechanisms regulating angiogenesis in HNSCC and critically discusses current and emerging pharmacological strategies targeting these pathways. Particular emphasis is placed on VEGF/VEGFR signaling, the integration of miRNA and exosome biology, resistance mechanisms, and translational perspectives for biomarker-guided personalized therapy. The novelty of this review lies in the systematic integration of miRNA- and exosome-mediated angiogenic regulation, therapeutic resistance pathways, and precision medicine strategies into a unified pharmacological framework, addressing gaps not fully covered by prior reviews focused primarily on VEGF-targeted agents.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Doctoral School, "Victor Babes" University of Medicine and Pharmacy Timisoara, E. Murgu Square, No. 2, 300041 Timisoara, Romania.
- Department II of Microscopic Morphology, Discipline of Histology, "Victor Babes" University of Medicine and Pharmacy Timisoara, E. Murgu Square, No. 2, 300041 Timisoara, Romania.
- Department of Obstetrics and Gynecology, "Victor Babes" University of Medicine and Pharmacy Timisoara, E. Murgu Square, No. 2, 300041 Timisoara, Romania.
- Faculty of Medicine and Pharmacy, University of Oradea, 410087 Oradea, Romania.
- Department of Surgery 1, "Victor Babes" University of Medicine and Pharmacy Timisoara, E. Murgu Square, No. 2, 300041 Timisoara, Romania.
- Center of Hepatobiliary and Pancreatic Surgery, "Victor Babes" University of Medicine and Pharmacy Timisoara, E. Murgu Square, No. 2, 300041 Timisoara, Romania.
ORCID-Profile: Dorin Novacescu, Alexia Manole, Radu Gheorghe Dan, Flavia Zara
Förderung
- Victor Babeș University of Medicine and Pharmacy Timișoara
Zitieren
APA
Szekely, D., Armega-Anghelescu, A., Barb, A. C., Novacescu, D., Dumitru, C., Manole, A., Dan, R. G., & Zara, F. (2026). Pharmacological Targeting of Angiogenesis in Head and Neck Cancer: Molecular Mechanisms and Emerging Therapeutic Strategies. Pharmaceuticals, 19(6), 950. https://doi.org/10.3390/ph19060950
Vancouver
Szekely D, Armega-Anghelescu A, Barb AC, Novacescu D, Dumitru C, Manole A, et al. Pharmacological Targeting of Angiogenesis in Head and Neck Cancer: Molecular Mechanisms and Emerging Therapeutic Strategies. Pharmaceuticals. 2026;19(6):950. doi:10.3390/ph19060950
BibTeX
@article{Szekely2026,
author = {Szekely, Diana and Armega-Anghelescu, Antonia and Barb, Alina Cristina and Novacescu, Dorin and Dumitru, Catalin and Manole, Alexia and Dan, Radu Gheorghe and Zara, Flavia},
title = {Pharmacological Targeting of Angiogenesis in Head and Neck Cancer: Molecular Mechanisms and Emerging Therapeutic Strategies},
journal = {Pharmaceuticals},
year = {2026},
volume = {19},
number = {6},
pages = {950},
doi = {10.3390/ph19060950}
}
EUVIMED